InMed Pharmaceuticals to Webcast Live at Life Sciences Investor Forum June 24th
June 22 2021 - 12:29PM
InMed Pharmaceuticals Inc. (“InMed” or the
“Company”) (Nasdaq: INM), a clinical-stage company developing
cannabinoid-based pharmaceutical drug candidates as well as
manufacturing technologies for pharmaceutical-grade rare
cannabinoids, today announced that Eric. A. Adams, President
and CEO of InMed will present live at LifeSciencesInvestorForum.com
on June 24th.
DATE: Thursday, June 24th
TIME: 12:30PM ETLINK:
https://bit.ly/3c7Ertp
This will be a live, interactive online event where investors
are invited to ask the company questions in real-time. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
It is recommended that investors pre-register and run the online
system check to expedite participation and receive event
updates.
Learn more about the event at
www.lifesciencesinvestorforum.com.
Recent Company Highlights:
- InMed increased the yield of their
proprietary IntegraSyn™ rare cannabinoid manufacturing approach to
5 g/L, further improving the overall economics in advance of
commercial scale production
- InMed’s rare cannabinoid yield of
5 g/L significantly exceeds currently reported industry
yields, further validating the IntegraSyn™ manufacturing approach
as a commercially viable solution for large-scale,
pharmaceutical-grade GMP production of rare cannabinoids
- InMed submits clinical trial
applications to evaluate INM-755 (cannabinol) cream in a Phase 2
trial for Epidermolysis Bullosa
About InMedInMed
Pharmaceuticals is a clinical-stage company developing a pipeline
of cannabinoid-based pharmaceutical drug candidates, initially
focused on the therapeutic benefits of cannabinol (“CBN”) and is
developing IntegraSyn™ to produce pharmaceutical-grade
cannabinoids. The Company is dedicated to delivering new
therapeutic alternatives to patients who may benefit from
cannabinoid-based pharmaceutical drugs. For more information,
visit www.inmedpharma.com.
About Life Sciences Investor ForumLife Sciences
Investor Forum is the leading proprietary investor conference
series that provides an interactive forum for Life Sciences
companies to meet with and present directly to investors.
A real-time solution for investor engagement, Life Sciences
Investor Forum is powered by Intrado Digital Media and specifically
designed for more efficient investor access. Replicating the look
and feel of on-site investor conferences, Life Sciences Investor
Forum combines leading-edge conferencing and investor
communications capabilities with a comprehensive global investor
audience network.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: presenting at the LifeSciencesInvestorForum.com
on June 24, 2021; developing a pipeline of cannabinoid-based
medications in diseases with high unmet medical need; developing
manufacturing technologies for pharmaceutical-grade rare
cannabinoids; further improving the economics of IntegraSyn™ in
advance of large-scale production; IntegraSyn™ being an important
and commercially viable solution for large-scale,
pharmaceutical-grade GMP production of rare cannabinoids; and
delivering new therapeutic alternatives to patients that may
benefit from cannabinoid-based medicines.
While InMed considers these assumptions to be reasonable, these
assumptions are inherently subject to significant business,
economic, competitive, market and social uncertainties and
contingencies. Additionally, there are known and unknown risk
factors which could cause InMed’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. Known risk factors
include, among others: the outbreak and impact of COVID-19 may
worsen; commercial viability and large-scale production may not be
possible within anticipated timelines or at all; the manufacturing
process may not be GMP-ready for pharmaceutical quality production;
demand or interest for InMed's products may decrease or cease; and
economic and market conditions may become unstable or unfavorable.
A more complete discussion of the risks and uncertainties facing
InMed is disclosed in InMed’s filings with the Securities and
Exchange Commission, including our Form 10-Q for the quarterly
period ended September 30, 2020 filed with the SEC on December 17,
2020, and the most recent Annual Information Form filed with
Canadian securities regulatory authorities on SEDAR at
www.sedar.com.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
CONTACTS:
Colin Clancy
Senior Director
Investor Relations
+1 604 416 0999
cclancy@inmedpharma.com
Life Sciences Investor Forum
John M. Viglotti
SVP Corporate Services, Investor Access
(212) 220-2221
johnv@lifesciencesinvestorforum.com
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Mar 2024 to Apr 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Apr 2023 to Apr 2024